[Hypersensitivity reactions to cancer chemotherapeutic agents].
Although hypersensitivity reactions to the anticancer drug are rare, since the reactions occasionally are clinical problems enough, that measure is important. The backgrounds (the etiologic mechanisms, the frequency, and etc) differ by each, therefore the knowledge for each medicine is required for measures including prediction and the prevention. This paper reviews the sensitivity reactions of various anticancer drugs (especially, paclitaxel, cisplatin and carboplatin) also including the molecular targeting drugs (trastuzumab, rituximab).
Sato
Atsushi
A
Department of Internal Medicine, Showa University Northern Yokohama Hospital, 35-1 Chigasaki-cho, Tsuzuki-ku, Yokohama, Kanagawa 224-8503, Japan.
Sakashita
Akiko
A
Taguchi
Susumu
S
D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002945:Cisplatin / Q000009:adverse effects; D003875:Drug Eruptions / Q000188:drug therapy / Q000209:etiology; D004342:Drug Hypersensitivity / Q000175:diagnosis / Q000517:prevention & control*; D005334:Fever / Q000139:chemically induced / Q000188:drug therapy; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000009:adverse effects; D012120:Respiration Disorders / Q000139:chemically induced / Q000628:therapy; D000069283:Rituximab; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D006634:Histamine H1 Antagonists; D000069283:Rituximab; D000068878:Trastuzumab; D017239:Paclitaxel; D002945:Cisplatin